Catherine Mezzacappa, MD, MPH
she/her/hers
Clinical FellowAbout
Research
Publications
2025
Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort.
John B, Bastaich D, Mezzacappa C, Ferreira R, Hentschel A, Samos A, Mahmud N, Taddei T, Kaplan D, Serper M, Dahman B. Identifying Metabolic Dysfunction-Associated Steatotic Liver Disease Using Natural Language Processing in a US National Cohort. The American Journal Of Gastroenterology 2025 PMID: 39950372, DOI: 10.14309/ajg.0000000000003321.Peer-Reviewed Original ResearchElectronic health recordsCardiometabolic risk factorsAlcohol useChart reviewRetrospective study of participantsStudy of participantsLiver diseaseSteatotic liver diseaseIncreased alcohol intakeEligible veteransICD-9/10 codesHealth recordsNational cohortAlcohol intakeEvidence of hepatic steatosisEpidemiological studiesNatural language processing algorithmsRisk factorsStudy cohortOutcome studiesVeteransCohortClinical entityRetrospective studyMetabolic dysfunctionMortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study
Njei B, Mezzacappa C, John B, Serper M, Kaplan D, Taddei T, Mahmud N. Mortality, Hepatic Decompensation, and Cardiovascular Outcomes in Lean vs. Non-lean MASLD Cirrhosis: A Veterans Affairs Cohort Study. Digestive Diseases And Sciences 2025, 70: 802-813. PMID: 39779587, PMCID: PMC11839701, DOI: 10.1007/s10620-024-08764-4.Peer-Reviewed Original ResearchConceptsNon-lean individualsAll-cause mortalityMajor adverse cardiovascular eventsIncreased risk of all-cause mortalityRisk of all-cause mortalityVeterans Health AdministrationRisk of hepatic decompensationPrevalence of diabetesRisk of cardiovascular mortalityHepatic decompensationHigher mortality riskCardiovascular-related mortalityCox proportional hazards modelsCohort study of patientsCardiovascular outcomesIncident major adverse cardiovascular eventsRetrospective cohort study of patientsProportional hazards modelNon-HispanicRetrospective cohort studyCompeting risk regressionHealth AdministrationMultivariate Cox proportional hazards modelLean individualsAssessed associations
2024
Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death.
Vutien P, Barnard Giustini A, Kim N, Moon A, Hsu C, Mezzacappa C, Borgerding J, Johnson K, VoPham T, Berry K, Beste L, Kaplan D, Taddei T, Ioannou G. Validation and expansion of Baveno VII criteria for cACLD and CSPH based on liver stiffness and platelet count: Correlation with risk of hepatic decompensation and death. Hepatology 2024 PMID: 39689352, DOI: 10.1097/hep.0000000000001183.Peer-Reviewed Original ResearchClinically significant portal hypertensionRisk of deathHepatic decompensationLiver stiffnessChronic liver diseasePlatelet countStratify risk of deathLiver diseaseRisk of hepatic decompensationMedian follow-upRisk of adverse outcomesSignificant portal hypertensionAssociated with risk of adverse outcomesRisk of decompensationAssociated with riskPortal hypertensionStratify riskFollow-upDecompensationAdverse outcomesCACLDPlatelet measuresPatientsPlateletDeathValidation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national United States cohort with cirrhosis
Mezzacappa C, Ochoa-Allemant P, Serper M, Taddei T, John B, Kaplan D, Mahmud N. Validation and epidemiologic definition of the novel steatotic liver disease nomenclature in a national United States cohort with cirrhosis. Clinical Gastroenterology And Hepatology 2024 PMID: 39689774, DOI: 10.1016/j.cgh.2024.10.035.Peer-Reviewed Original ResearchAlcohol-associated liver diseaseCardiometabolic risk factorsAlcohol use disorderSteatotic liver diseaseLiver diseaseLow high-density lipoproteinChild-Turcotte-Pugh classIncidence rateIncident hepatocellular carcinomaIncreased alcohol intakeAlcohol useClinically relevant definitionAll-cause mortalityHigher hazard of mortalityNational cohort of veteransUnited States cohortCohort of veteransAcute cardiac eventsHigh-density lipoproteinHazard of mortalityHazardous alcohol useAlcohol intakeCardiac eventsAlcohol exposureHepatocellular carcinomaHepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status
Re V, Newcomb C, Carbonari D, Mezochow A, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Torgersen J. Hepatotoxicity Score: A New Method to Adjust for Use of Potentially Hepatotoxic Medications by Chronic Liver Disease Status. Pharmacoepidemiology And Drug Safety 2024, 33: e70069. PMID: 39662972, PMCID: PMC11634562, DOI: 10.1002/pds.70069.Peer-Reviewed Original ResearchConceptsProton pump inhibitor initiationHazard ratioVeterans Health AdministrationSevere acute liver injuryProton pump inhibitorsChronic liver diseaseAcute liver injuryRates of hospitalizationSafety of medicationsPPI initiativesHealth AdministrationLiver disease statusMedication exposurePharmacoepidemiological studiesMedicationConfoundingScoresReports of hepatotoxicityDisease statusHepatotoxic medicationsDrug exposurePump inhibitorsHepatotoxic drugsOutpatient initiationHepatic safetyGastro Digest: The Revised REACH-B Model Predicts Hepatocellular Carcinoma in Patients with Chronic Hepatitis B
Mezzacappa C. Gastro Digest: The Revised REACH-B Model Predicts Hepatocellular Carcinoma in Patients with Chronic Hepatitis B. Gastroenterology 2024 PMID: 39622300, DOI: 10.1053/j.gastro.2024.11.017.Peer-Reviewed Original ResearchSevere Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data
Torgersen J, Mezochow A, Newcomb C, Carbonari D, Hennessy S, Rentsch C, Park L, Tate J, Bräu N, Bhattacharya D, Lim J, Mezzacappa C, Njei B, Roy J, Taddei T, Justice A, Re V. Severe Acute Liver Injury After Hepatotoxic Medication Initiation in Real-World Data. JAMA Internal Medicine 2024, 184: 943-952. PMID: 38913369, PMCID: PMC11197444, DOI: 10.1001/jamainternmed.2024.1836.Peer-Reviewed Original ResearchIncidence rateUS Department of Veterans AffairsMedication initiationDepartment of Veterans AffairsInitiation of medicationVeterans AffairsMain OutcomesPotential of medicationsOutpatient settingDischarge diagnosisCohort studyDay of admissionCase reportReal World DataReport countsMedicationMedical cohortSevere acute liver injuryUS DepartmentFollow-upAcute liver injuryHospitalCohortHepatotoxic medicationsIncidenceIntegrated Telemedicine to Treat HCV Through Opioid Treatment Programs
Mezzacappa C. Integrated Telemedicine to Treat HCV Through Opioid Treatment Programs. Gastroenterology 2024, 168: 176. PMID: 39025413, DOI: 10.1053/j.gastro.2024.07.010.Peer-Reviewed Original ResearchScreening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure
Mezzacappa C, Kim N, Vutien P, Kaplan D, Ioannou G, Taddei T. Screening for Hepatocellular Carcinoma and Survival in Patients With Cirrhosis After Hepatitis C Virus Cure. JAMA Network Open 2024, 7: e2420963. PMID: 38985470, PMCID: PMC11238019, DOI: 10.1001/jamanetworkopen.2024.20963.Peer-Reviewed Original ResearchConceptsHepatitis C virus cureHepatitis C virusAssociated with improved overall survivalHepatocellular carcinoma diagnosisEarly-stage hepatocellular carcinomaImproved overall survivalOverall survivalHepatocellular carcinomaFollow-upHCC screeningCurative treatmentCumulative incidence of hepatocellular carcinomaDirect-acting antiviral (DAA) therapyCohort studyVeterans Affairs health care systemIncidence of hepatocellular carcinomaRisk of hepatocellular carcinomaCohort study of personsHepatitis C virus cirrhosisDiagnosis of hepatocellular carcinomaLikelihood of curative treatmentYears of follow-upHealth care systemHepatocellular carcinoma screeningHCV-related cirrhosisReview of the cost-effectiveness of surveillance for hereditary pancreatic cancer
Wang L, Levinson R, Mezzacappa C, Katona B. Review of the cost-effectiveness of surveillance for hereditary pancreatic cancer. Familial Cancer 2024, 23: 351-360. PMID: 38795221, PMCID: PMC11255025, DOI: 10.1007/s10689-024-00392-1.Peer-Reviewed Original ResearchHigh-risk individualsHereditary pancreatic cancerSusceptibility to pancreatic cancerPancreatic cancer riskFamily history of PCSurveillance strategiesPancreatic cancerCost-effectiveness of surveillanceHistory of PCCost-effectiveness studiesCost-effectiveCancer riskCost-effectiveness analysisPancreatic surveillanceHigh-risk groupOptimal surveillance strategyFamily historyNew-onset diabetesRisk individualsSporadic PCHealth benefitsPotential health benefitsPC diagnosisSub-groupsSurveillance
Academic Achievements & Community Involvement
News
News
- September 10, 2024
Liver Cancer Screening Post-Hep C Cure Improves Survival
- September 19, 2023
Liver Center Retreat Highlights Breadth of Liver Research at Yale
- August 01, 2023
Fellow Focus in Four: Catherine Mezzacappa, MD, MPH, Digestive Diseases
- May 12, 2020
Good Times Never Seemed So Good
Get In Touch
Contacts
Events
Jun 202524Tuesday
- Yale OnlyCatherine Mezzacappa, MD, MPH - Weizhe Zhong